XM không cung cấp dịch vụ cho cư dân của Mỹ.
S
S

Sage


Tin tức

SAGE Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.53​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of $-3.37. The mean expectation of nineteen analysts for the quarter was for a loss of $1.53 per share.
S

SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.53 a share - Earnings Preview

SAGE Therapeutics Inc expected to post a loss of $1.53 a share - Earnings Preview SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on October 29 for the period ending September 30 2024 The Cambridge Massachusetts-based company is expected to report a 297.7% increase in revenue to $10.802 million from $2.72 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
S

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Wall Street rose on Thursday, with the S&P 500 and the Dow briefly reaching record highs, as chip stocks surged on TSMC's upbeat forecast and stronger-than-expected monthly retail sales indicated a robust U.S. consumer. .N At 13:36 ET, the Dow Jones Industrial Average .DJI was up 0
A
B
C
E
I
N
N
S
S
S
U
U
U
U
A
E

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street gained on Thursday, with the S&P 500 and the Dow touching intraday record highs, driven by TSMC's upbeat forecast and a bigger-than-expected rise in monthly retail sales indicating a strong U.S.
A
B
C
E
I
N
N
R
S
S
S
U
U
U
U
T
U
W
W
A
E
M
S

Sage to lay off more than half of R&D team, shares fall

BUZZ-Sage to lay off more than half of R&D team, shares fall ** Sage Therapeutics' shares SAGE.O fall 5.5% to $6.87 in morning trade ** Co says it will lay off more than 165 employees, including more than half of its R&D team, as part of reorganization plan ** To prioritize launch of postpartum depression pill Zurzuvae, which has been jointly devel
B
S

SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary

BRIEF-SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS: APPROVED SEPARATION OF KIMI IGUCHI, CFO, AND ANNE MARIE COOK, SENIOR VP, GENERAL COUNSEL, AND SECRETARY Source text for Eikon: [ID:n0001193125-24-238425] Further
S

SAGE Therapeutics Says To Reduce Workforce By About 33%

BRIEF-SAGE Therapeutics Says To Reduce Workforce By About 33% Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO PRIORITIZE ZURZUVAE® COMMERCIALIZATION AND FOCUS ITS DEVELOPMENT PORTFOLIO SAGE THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 33% SAGE THERAPEUTICS INC - REORGANIZATION TO
S

Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees

UPDATE 2-Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees Adds details on CFO leaving company in paragraphs 1, 3 and background in paragraphs 8-10 Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 employees as part of a reorganization plan that aims to focus on the launch of its postpartum depression pill.
B
S

Sage Therapeutics to lay off more than 165 employees

Sage Therapeutics to lay off more than 165 employees Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday it will lay off more than 165 employees or about 33% of the company's total workforce. Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta
S

U.S. Autozone, State Street, UnitedHealth

U.S. RESEARCH ROUNDUP-Autozone, State Street, UnitedHealth Oct 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Autozone, State Street and UnitedHealth, on Wednesday. HIGHLIGHTS * Autozone Inc AZO.N : Roth MKM resumes coverage with buy rating; price target $3,634 * Goldman Sachs GS.N : Barclays raises target price to $588 from $565 * ServiceNow Inc NOW.N : Jefferies raises target price to $1,100 from $900 * State St
C
G
S
T
F
G
S
A

U.S. Aflac, Lincoln National, Prudential Financial

U.S. RESEARCH ROUNDUP-Aflac, Lincoln National, Prudential Financial Oct 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aflac, Lincoln National and Prudential Financial, on Wednesday. HIGHLIGHTS * Aflac Inc AFL.N : TD Cowen initiates coverage with hold rating; price target $102 * Corebridge Financial Inc CRBG.N : TD Cowen initiates coverage with buy rating * Lincoln National Corp LNC.N : TD Cowen initiates coverage
A
B
G
H
N
P
S
S
S
A
V
A
A
E
G
L
M

U.S. STOCKS Nvidia, Roblox, Honeywell

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Roblox, Honeywell Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Tuesday, as investors shifted their attention to the upcoming third-quarter earnings season and inflation data for hints on the Federal Reserve's future rate decisions.
C
M
M
N
Q
S
L
R
W
U
U
E
S
T

U.S. STOCKS Copper miners, PepsiCo, Casinos

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, PepsiCo, Casinos Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures bounced back on Tuesday from a selloff in the previous session, as investors turned their focus on key inflation data and third-quarter earnings later this week for fresh insights into the Federal Reserve's interest rate path.
M
M
P
Q
S
L
R
W
U
E
T

Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide

UPDATE 3-Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide Adds background in paragraph 2, analyst comment in paragraph 5; updates shares Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
B
S

Sage falls on plans to stop development of Alzheimer's disease drug

BUZZ-Sage falls on plans to stop development of Alzheimer's disease drug ** Shares of Sage Therapeutics SAGE.O down 13% at $5.86 before the bell ** SAGE plans to stop further development of its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a mid-stage study ** Dalzanemdor was being tested to treat
S

Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease

BRIEF-Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease Oct 8 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 LIGHTWAVE STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT AND
S

Sage Therapeutics to discontinue development of Alzheimer’s drug

Sage Therapeutics to discontinue development of Alzheimer’s drug Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial. Reporting by Christy Santhosh; Editing by Pooja Desai
S

Sage Therapeutics falls after Biogen terminates tremor drug partnership

BUZZ-Sage Therapeutics falls after Biogen terminates tremor drug partnership ** Shares of drug developer Sage Therapeutics SAGE.O fall 1% to $6.95 premarket ** Company says partner Biogen BIIB.O has terminated a licensing deal for Sage's experimental drug to treat essential tremor, effective February 2025 ** Sage had discontinued development of the
B
S

SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program

BRIEF-SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program Sept 26 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES DISCONTINUATION OF THE COLLABORATION WITH BIOGEN ON THE SAGE-324 PROGRAM SAGE THERAPEUTICS INC - BIOGEN TERMINATES RIGHTS UNDER SAGE-324 PROGRAM SAGE THERAPEUTICS I
S

Incorrect research alert on Sage Therapeutics Inc withdrawn

ADVISORY-Incorrect research alert on Sage Therapeutics Inc withdrawn An alert on J.P. Morgan cutting its price target on Sage Therapeutics Inc SAGE.O is incorrect and has been withdrawn. The brokerage lowered its PT on Sage Group PLC, an unrelated company. For the correct research alert on Sage Group PLC, click here . STORY_NUMBER: FWN3L714D STORY_
S



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.